Commentary: Why Haven't We Found an Effective Treatment for COVID-19?
作者信息
Brzoska Josef, von Eick Harald, Hündgen Manfred
机构信息
Retired, Laupheim, Germany.
出版信息
Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.
Abstract
摘要
相似文献
1
Commentary: Why Haven't We Found an Effective Treatment for COVID-19?评论：为何我们尚未找到针对新冠病毒病的有效治疗方法？
Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.
2
Why Haven't We Found an Effective Treatment for COVID-19?为什么我们还没有找到针对新冠病毒的有效治疗方法？
Front Immunol. 2021 Mar 31;12:644850. doi: 10.3389/fimmu.2021.644850. eCollection 2021.
3
SARS-CoV-2 vaccination in liver transplant recipients: We still haven't found what we are looking for.肝移植受者接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗：我们仍未找到我们所寻找的答案。
Ann Hepatol. 2023 May-Jun;28(3):101081. doi: 10.1016/j.aohep.2023.101081. Epub 2023 Mar 5.
4
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
5
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.用恢复期血浆治疗 COVID-19：从过去的冠状病毒爆发中吸取的教训。
Clin Microbiol Infect. 2020 Oct;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005. Epub 2020 Aug 11.
6
Roles of Type I and III Interferons in COVID-19.I 型和 III 型干扰素在 COVID-19 中的作用。
Yonsei Med J. 2021 May;62(5):381-390. doi: 10.3349/ymj.2021.62.5.381.
7
Persistent SARS-CoV-2 infection and the risk for cancer.持续的 SARS-CoV-2 感染与癌症风险。
Med Hypotheses. 2020 Oct;143:109882. doi: 10.1016/j.mehy.2020.109882. Epub 2020 May 28.
8
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.COVID-19 风险和结局在接受生物制剂或全身皮质类固醇治疗的成年哮喘患者中的：全国真实世界证据。
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
9
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.严重急性呼吸综合征（SARS）、中东呼吸综合征（MERS）和严重急性呼吸综合征冠状病毒 2（COVID-19）治疗：专利述评。
Expert Opin Ther Pat. 2020 Aug;30(8):567-579. doi: 10.1080/13543776.2020.1772231. Epub 2020 Jun 7.
10
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
引用本文的文献
1
Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?新冠疫情中的干扰素：错失在III期临床试验中证明疗效的机会？
Front Med (Lausanne). 2023 May 30;10:1198576. doi: 10.3389/fmed.2023.1198576. eCollection 2023.
2
Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD) for COVID-19.用于 COVID-19 的人免疫系统 (HIS) 人源化小鼠模型 (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2RγcKO.NOD)。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2048622. doi: 10.1080/21645515.2022.2048622. Epub 2022 Mar 29.
本文引用的文献
1
Why Haven't We Found an Effective Treatment for COVID-19?为什么我们还没有找到针对新冠病毒的有效治疗方法？
Front Immunol. 2021 Mar 31;12:644850. doi: 10.3389/fimmu.2021.644850. eCollection 2021.
2
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.干扰素治疗在重症 COVID-19 中的作用：COVIFERON 随机对照试验。
Sci Rep. 2021 Apr 13;11(1):8059. doi: 10.1038/s41598-021-86859-y.
3
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.佩格干扰素 lambda-1a 治疗门诊轻至中度 COVID-19 患者的随机安慰剂对照试验。
Nat Commun. 2021 Mar 30;12(1):1967. doi: 10.1038/s41467-021-22177-1.
4
Interferon-based therapies in COVID-19.COVID-19中基于干扰素的疗法。
Int Immunopharmacol. 2021 Apr;93:107415. doi: 10.1016/j.intimp.2021.107415. Epub 2021 Jan 28.
5
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
6
Potential role of interferons in treating COVID-19 patients.干扰素在治疗 COVID-19 患者中的潜在作用。
Int Immunopharmacol. 2021 Jan;90:107171. doi: 10.1016/j.intimp.2020.107171. Epub 2020 Nov 3.
7
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.吸入用干扰素 β-1a（SNG001）治疗 SARS-CoV-2 感染的安全性和有效性：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.
8
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial.干扰素 β-1b 治疗重症 COVID-19：一项随机临床试验。
Int Immunopharmacol. 2020 Nov;88:106903. doi: 10.1016/j.intimp.2020.106903. Epub 2020 Aug 24.
9
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
10
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.
Zotero 插件